Koutsogianni Amalia Despoina, Liberopoulos Evangelos, Tellis Konstantinos, Tselepis Alexandros D
Department of Internal Medicine, Faculty of Medicine, University of Ioannina, Ioannina, Greece.
Department of Chemistry, Atherothrombosis Research Centre/Laboratory of Biochemistry, University of Ioannina, Ioannina, Greece.
Eur J Clin Invest. 2022 Apr;52(4):e13710. doi: 10.1111/eci.13710. Epub 2021 Nov 27.
Over the past few years, there has been an undiminished interest in lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPLs), mainly carried on this lipoprotein. Elevated Lp(a) has been established as an independent causal risk factor for cardiovascular disease. OxPLs play an important role in atherosclerosis. The main questions that remain to be answered, however, is to what extent OxPLs contribute to the atherogenicity of Lp(a), what effect hypolipidaemic medications may have on their levels and the potential clinical benefit of their reduction. This narrative review aimed to summarize currently available data on OxPLs and cardiovascular risk, as well as the effect of established and emerging hypolipidaemic medications on Lp(a)-OxPLs.
在过去几年中，人们对脂蛋白(a)[Lp(a)]和氧化磷脂(OxPLs)的兴趣一直未减，氧化磷脂主要存在于这种脂蛋白上。Lp(a)升高已被确认为心血管疾病的独立因果风险因素。氧化磷脂在动脉粥样硬化中起重要作用。然而，仍有待回答的主要问题是，氧化磷脂在多大程度上导致Lp(a)的致动脉粥样硬化性，降血脂药物可能对其水平有何影响，以及降低氧化磷脂的潜在临床益处。这篇叙述性综述旨在总结目前关于氧化磷脂与心血管风险的可用数据，以及已有的和新出现的降血脂药物对Lp(a)-氧化磷脂的影响。
